Purpose Your Health Experience Professionals Commitment Press Investors Work with us ESG Plan 2021-2023 Almirall's roadmap towards a more sustainable future More information Get to know them The stories behind Almirall Know all of them Nerea nos cuenta cómo se sienten los pacientes con psoriasis. Descubre más Óscar nos habla sobre su día a día con la psoriasis. Descubre más Nathalie nos cuenta su experiencia trabajando para Almirall Descubre más Escoge tu Almirall Encuentra contenido destacado específicamente seleccionado para ti. Pacientes Inversores Profesionales Talento Almirall en cifras Nuestra dedicación a la ciencia y a las personas se puede medir Our suppliers, decisive to achieve our Noble Purpose The proper selection of suppliers, aligned with our values and committed to the world of health, contributes to the success of our business. Go to Suppliers QUICK LINKS Our purpose Your Health Our experience Our commitment Our stories Corporate governance ALMIRALL Media Investors Work with us Associations Providers Professionals CONTACT US Contact Report an adverse effect Subscribe FOLLOW US Catch up on Almirall on our social networks 59CD2BBB-3B40-4519-9BFA-34066ED9DC2D Created with sketchtool. B65C6E50-1BD0-4CD4-B046-33EE4DBB16BD Created with sketchtool. Copyright 2020 © Almirall, SA All rights reserved Privacy Policy Terms of use Cookies Policy Site Map We use third-party and own cookies for statistical purposes. You can configure yourpreferences to reject or accept our cookies. If you need more information, read our Cookies Policy . ACCEPT ALL

Purpose Your Health Experience Professionals Commitment Press Investors Work with us Investigation and development Therapeutic areas Our products Partnering Experience Investigation and development Pipeline Projects in advanced phases Last update, September 2021. Indication See all Commercial Name / Molecule See all Expected Launch See all Phase See all Geography See all Indication Commercial Name / Molecule Expected Launch Phase I Phase II Phase III Under Registration Approval Geography Actinic Keratosis Europe EU H2 2021 EU Psoriasis Wynzora® * EU H2 2021 / Q1 2022 EU Atopic dermatitis Lebrikizumab 2023 EU Acne Sarecycline 2023 Submission China Onychomycosis Efinaconazole 2023 ** EU * Wynzora® is the approved brand name in the US and France. ** Depending on regulatory pathway. Preclinical Research and Development Programs QUICK LINKS Our purpose Your Health Our experience Our commitment Our stories Corporate governance ALMIRALL Media Investors Work with us Associations Providers Professionals CONTACT US Contact Report an adverse effect Subscribe FOLLOW US Catch up on Almirall on our social networks 59CD2BBB-3B40-4519-9BFA-34066ED9DC2D Created with sketchtool. B65C6E50-1BD0-4CD4-B046-33EE4DBB16BD Created with sketchtool. Copyright 2020 © Almirall, SA All rights reserved Privacy Policy Terms of use Cookies Policy Site Map We use third-party and own cookies for statistical purposes. You can configure yourpreferences to reject or accept our cookies. If you need more information, read our Cookies Policy . ACCEPT ALL